More than 3,000 people in Britain claim that they or their relatives developed ovarian cancer or mesothelioma after using the ...
Merck (NYSE:MRK) announced on Thursday that its Phase 3 KEYNOTE-B96 trial for its anti-PD-1 therapy Keytruda reached the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback